Methylglyoxal as a prognostic factor in patients with chronic kidney disease.
Aged
Arginine
/ analogs & derivatives
Biomarkers
/ blood
Cardiovascular Diseases
/ blood
Deoxyglucose
/ analogs & derivatives
Diabetic Nephropathies
/ blood
Disease Progression
Female
Humans
Japan
Kidney Failure, Chronic
/ blood
Lysine
/ analogs & derivatives
Male
Middle Aged
Predictive Value of Tests
Prospective Studies
Pyruvaldehyde
/ blood
Renal Insufficiency, Chronic
/ blood
Risk Factors
Time Factors
Up-Regulation
advanced glycation end products
cardiovascular disease
chronic kidney disease
end-stage kidney disease
Journal
Nephrology (Carlton, Vic.)
ISSN: 1440-1797
Titre abrégé: Nephrology (Carlton)
Pays: Australia
ID NLM: 9615568
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
accepted:
31
10
2018
pubmed:
9
11
2018
medline:
11
2
2020
entrez:
9
11
2018
Statut:
ppublish
Résumé
Advanced glycation end products and their precursors cause vascular damage through oxidative stress. We investigated the hypothesis that methylglyoxal (MG), 3-deoxyglucosone (3-DG) and pentosidine influence outcomes of chronic kidney disease (CKD) patients. We conducted a 3 years prospective observational study involving 150 outpatients at CKD stages 3-5. At enrolment, MG, 3-DG and pentosidine plasma concentrations were measured; patients were divided into tertiles according to the concentration of each substance. The primary endpoint was death, a cardiovascular event or end-stage renal disease. Survival analysis was performed using the Cox regression model. The patients' mean age was 62 ± 12 years, 97 were men, and 20 had diabetic nephropathy. The mean estimated glomerular filtration rate was 25.0 ± 12.1 mL/min per 1.73 m Methylglyoxal has a close clinical association with CKD. Higher MG concentrations may contribute renal function deterioration in CKD. In CKD patients, MG concentration might be useful when determining the prognosis.
Substances chimiques
Biomarkers
0
3-deoxyglucose
2490-91-7
Pyruvaldehyde
722KLD7415
Arginine
94ZLA3W45F
Deoxyglucose
9G2MP84A8W
pentosidine
BJ4I2X2CQJ
Lysine
K3Z4F929H6
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
943-950Subventions
Organisme : Chugai Pharmaceutical
Informations de copyright
© 2018 Asian Pacific Society of Nephrology.
Références
Jha V, Garcia-Garcia G, Iseki K et al. Chronic kidney disease: Global dimension and perspectives. Lancet 2013; 382: 260-72.
Schiffrin EL, Lipman ML, Mann JFE. Chronic kidney disease: Effects on the cardiovascular system. Circulation 2007; 116: 85-97.
Saulnier PJ, Wheelock KM, Howell S et al. Advanced glycation end products predict loss of renal function and correlate with lesions of diabetic kidney disease in American Indians with type 2 diabetes. Diabetes 2016; 65: 3744-53.
Hou FF, Ren H, Owen WF Jr et al. Enhanced expression of receptor for advanced glycation end products in chronic kidney disease. J. Am. Soc. Nephrol. 2004; 15: 1889-96.
Linden E, Cai W, He JC et al. Endothelial dysfunction in patients with chronic kidney disease results from advanced glycation end products (AGE)-mediated inhibition of endothelial nitric oxide synthase through RAGE activation. Clin. J. Am Soc. Nephrol. 2008; 3: 691-8.
Koyama Y, Takeishi Y, Arimoto T et al. High serum level of pentosidine, an advanced glycation end product (AGE), is a risk factor of patients with heart failure. J. Card. Fail. 2007; 13: 199-206.
Kerkeni M, Saidi A, Bouzidi H, Letaief A, Ben Yahia S, Hammami M. Pentosidine as a biomarker for microvascular complications in type 2 diabetic patients. Diab. Vasc. Dis. Res. 2013; 10: 239-45.
Abordo EA, Minhas HS, Thornalley PJ. Accumulation of alpha-oxoaldehydes during oxidative stress: A role in cytotoxicity. Biochem. Pharmacol. 1999; 58: 641-8.
Dobler D, Ahmed N, Song L, Eboigbodin KE, Thornalley PJ. Increased dicarbonyl metabolism in endothelial cells in hyperglycemia induces anoikis and impairs angiogenesis by RGD and GFOGER motif modification. Diabetes 2006; 55: 1961-9.
Akhand AA, Hossain K, Mitsui H et al. Glyoxal and methylglyoxal trigger distinct signals for map family kinases and caspase activation in human endothelial cells. Free Radic. Biol. Med. 2001; 31: 20-30.
Niwa T. 3-Deoxyglucosone: Metabolism, analysis, biological activity, and clinical implication. J. Chromatogr. B Biomed. Sci. Appl. 1999; 731: 23-36.
Niwa T, Tsukushi S. 3-deoxyglucosone and AGEs in uremic complications: Inactivation of glutathione peroxidase by 3-deoxyglucosone. Kidney Int. Suppl. 2001; 78: S37-41.
Nakayama K, Nakayama M, Iwabuchi M et al. Plasma alpha-oxoaldehyde levels in diabetic and nondiabetic chronic kidney disease patients. Am. J. Nephrol. 2008; 28: 871-8.
Bento CF, Fernandes R, Matafome P, Sena C, Seica R, Pereira P. Methylglyoxal-induced imbalance in the ratio of vascular endothelial growth factor to angiopoietin 2 secreted by retinal pigment epithelial cells leads to endothelial dysfunction. Exp. Physiol. 2010; 95: 955-70.
Cardoso S, Carvalho C, Marinho R et al. Effects of methylglyoxal and pyridoxamine in rat brain mitochondria bioenergetics and oxidative status. J. Bioenerg. Biomembr. 2014; 46: 347-55.
Rabbani N, Thornalley PJ. The critical role of methylglyoxal and glyoxalase 1 in diabetic nephropathy. Diabetes 2014; 63: 50-2.
Ogawa S, Nakayama K, Nakayama M et al. Methylglyoxal is a predictor in type 2 diabetic patients of intima-media thickening and elevation of blood pressure. Hypertension 2010; 56: 471-6.
Matsuo S, Imai E, Horio M et al. Revised equations for estimated GFR from serum creatinine in Japan. Am. J. Kidney Dis. 2009; 53: 982-92.
Sanaka T, Funaki T, Tanaka T et al. Plasma pentosidine levels measured by a newly developed method using ELISA in patients with chronic renal failure. Nephron 2002; 91: 64-73.
Thornalley PJ. Glutathione-dependent detoxification of alpha-oxoaldehydes by the glyoxalase system: Involvement in disease mechanisms and antiproliferative activity of glyoxalase I inhibitors. Chem. Biol. Interact. 1998; 111-112: 137-51.
Maeta K, Izawa S, Inoue Y. Methylglyoxal, a metabolite derived from glycolysis, functions as a signal initiator of the high osmolarity glycerol-mitogen-activated protein kinase cascade and calcineurin/Crz1-mediated pathway in Saccharomyces cerevisiae. J. Biol. Chem. 2005; 280: 253-60.
Uribarri J, He JC. The low AGE diet: A neglected aspect of clinical nephrology practice? Nephron 2015; 130: 48-53.
Uribarri J, Peppa M, Cai W et al. Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J. Am Soc. Nephrol. 2003; 14: 728-31.
Stinghen AEM, Massy ZA, Vlassara H, Striker GE, Boullier A. Uremic toxicity of advanced Glycation end products in CKD. J. Am. Soc. Nephrol. 2016; 27: 354-70.
Rabbani N, Sebekova K, Sebekova K Jr, Heidland A, Thornalley PJ. Accumulation of free adduct glycation, oxidation, and nitration products follows acute loss of renal function. Kidney Int. 2007; 72: 1113-21.
Kumagai T, Nangaku M, Kojima I et al. Glyoxalase I overexpression ameliorates renal ischemia-reperfusion injury in rats. Am. J. Physiol. Renal Physiol. 2009; 296: F912-21.
Inagi R. Glycative stress and glyoxalase in kidney disease and aging. Biochem. Soc. Trans. 2014; 42: 457-60.
Rabbani N, Godfrey L, Xue M et al. Glycation of LDL by methylglyoxal increases arterial atherogenicity: A possible contributor to increased risk of cardiovascular disease in diabetes. Diabetes 2011; 60: 1973-80.
Chen X, Mori T, Guo Q et al. Carbonyl stress induces hypertension and cardio-renal vascular injury in Dahl salt-sensitive rats. Hypertens. Res. 2013; 36: 361-7.
Wu L, Juurlink BHJ. Increased methylglyoxal and oxidative stress in hypertensive rat vascular smooth muscle cells. Hypertension 2002; 39: 809-14.
Busch M, Franke S, Ruster C, Wolf G. Advanced glycation end-products and the kidney. Eur. J. Clin. Invest. 2010; 40: 742-55.
Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: A review. Diabetologia 2001; 44: 129-46.
Miyata T, van Ypersele de Strihou C, Kurokawa K, Baynes JW. Alterations in nonenzymatic biochemistry in uremia: Origin and significance of "carbonyl stress" in long-term uremic complications. Kidney Int. 1999; 55: 389-99.
Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: Sparking the development of diabetic vascular injury. Circulation 2006; 114: 597-605.
Hori O, Yan SD, Ogawa S et al. The receptor for advanced glycation end-products has a central role in mediating the effects of advanced glycation end-products on the development of vascular disease in diabetes mellitus. Nephrol. Dial. Transplant. 1996; 11: 13-6.
Furuya R, Kumagai H, Miyata T et al. High plasma pentosidine level is accompanied with cardiovascular events in hemodialysis patients. Clin. Exp. Nephrol. 2012; 16: 421-6.
Hanssen NMJ, Engelen L, Ferreira I et al. Plasma levels of advanced glycation endproducts Nε-(carboxymethyl)lysine, Nε-(carboxyethyl)lysine, and pentosidine are not independently associated with cardiovascular disease in individuals with or without type 2 diabetes: the Hoorn and CODAM studies. J. Clin. Endocrinol. Metab. 2013; 98: E1369-73.
Tanji N, Markowitz GS, Fu C et al. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J. Am. Soc. Nephrol. 2000; 11: 1656-66.